It’s done

Quote

anonymous said:
Who? The IBU idiots now selling Tepezza? All the successful reps who built the brand and made it what it is have left
Click to expand...

Tepezza has been a commercial failure which is why the company was sold. It isn't hitting the financial goals the company and more importantly what investors expect. Thus the stock price in the toilet which is what caused this to happen.

The first year selling Tepezza was fairly easy- you had patients that hadn't been treated- waiting to get treated. Once those patients went away the "successful reps that left" couldn't figure out how to pull patients not in those eye centers through. Which is where we are now. Not sure if the "IBU idiots" would be able to figure it out either- but it is apparent the legacy Tepezza people couldn't. It takes a special type of strategic rep to operate in rare disease and they weren't getting it done.
 


anonymous said:
Well if its between Horizon and the rejects who went to Chemocentryx I think Horizon employees will win out in an interview.
Click to expand...

What? It’s not going to be between us & them. They have their own viable product without & overweight salesforce. They have transitioned anyway, so there wouldn’t be an interviewing. We’re talking about being in competition with each other on the KXX team since there’s so damn many of us now with a weird split for specialties - one team has only one specialty & the other has all of the other specialties including the one that writes the most. We aren’t even selling a different indication..
 


anonymous said:
Well one because Tepzza isn't an in office injection its much more complicated to get patients from the office to the infusion chair. I know your initial reaction will be its the same or its no big deal- but in reality it is. And those that have done the job know this. A lot more pull through and a lot more hand holding. Just facts.
Click to expand...

sure, but 100 of the reps were selling ibuprofen 6 months ago. They have been trained on infusion buy and bill for 3 months. Amgen employees actively call on sites of care and have relationships. It may be just an injection, but they’ve been doing it for a hell of a lot longer. 50% of OBU is safe. It won’t remains whole.
 




anonymous said:
sure, but 100 of the reps were selling ibuprofen 6 months ago. They have been trained on infusion buy and bill for 3 months. Amgen employees actively call on sites of care and have relationships. It may be just an injection, but they’ve been doing it for a hell of a lot longer. 50% of OBU is safe. It won’t remains whole.
Click to expand...


How are they calling on SOCs with an injection? Anyway, The OBU will be the last team they touch. It’s the reason that they are buying the company.
 




anonymous said:
What? It’s not going to be between us & them. They have their own viable product without & overweight salesforce. They have transitioned anyway, so there wouldn’t be an interviewing. We’re talking about being in competition with each other on the KXX team since there’s so damn many of us now with a weird split for specialties - one team has only one specialty & the other has all of the other specialties including the one that writes the most. We aren’t even selling a different indication..
Click to expand...

If they restructure rhuem some amgen will get cut and some horizon will remain. And you are right we/they won't be interviewing most likely. Pfizer would be a different story. If I was a nephrology rep I would be most worried.
 


anonymous said:
How are they calling on SOCs with an injection? Anyway, The OBU will be the last team they touch. It’s the reason that they are buying the company.
Click to expand...
They aren’t calling on SOC bc it isn’t an infusion, drugs like aflibercept are administered in office. They are buy and bill with the office. Easy peasy, completely different than an infusion like Tepezza
 


anonymous said:
They aren’t calling on SOC bc it isn’t an infusion, drugs like aflibercept are administered in office. They are buy and bill with the office. Easy peasy, completely different than an infusion like Tepezza
Click to expand...

On their rheum team they have Enbrel & Otezla neither of which is administered in office (few may have biosim though). They also just did a restructure in rheum over there, so they are where they need to be. If there are cuts, then they will come from our side for our products.
 


anonymous said:
On their rheum team they have Enbrel & Otezla neither of which is administered in office (few may have biosim though). They also just did a restructure in rheum over there, so they are where they need to be. If there are cuts, then they will come from our side for our products.
Click to expand...

Enbrel is self administered sub q shot and otezla is a pill.
 




anonymous said:
If they restructure rhuem some amgen will get cut and some horizon will remain. And you are right we/they won't be interviewing most likely. Pfizer would be a different story. If I was a nephrology rep I would be most worried.
Click to expand...

The Neph team yes, they should worry. The ones really needing to be looking for new roles will be the Referral team
 


anonymous said:
The Neph team yes, they should worry. The ones really needing to be looking for new roles will be the Referral team
Click to expand...
Maybe some reps in rheum, especially the referral reps. Amgen just restructured their rheum, though, so they think that they are where they need to be in terms of size for their current products. They are not going to give Krystexxa as an extra product to sell. This isn’ primary care where you sell a multitude of products. The rheum team calls on podiatrists, too, which their rheum sales force does not, and, if they are going to make cuts, it would make more sense to cut the neph team & just add nephs as targets for the RSAMs like they used to do. So there’s 2 call points that their current rheum reps to call on. I think that the RSAMs are pretty safe for awhile…as safe as one can be in this industry.
 








anonymous said:
Maybe some reps in rheum, especially the referral reps. Amgen just restructured their rheum, though, so they think that they are where they need to be in terms of size for their current products. They are not going to give Krystexxa as an extra product to sell. This isn’ primary care where you sell a multitude of products. The rheum team calls on podiatrists, too, which their rheum sales force does not, and, if they are going to make cuts, it would make more sense to cut the neph team & just add nephs as targets for the RSAMs like they used to do. So there’s 2 call points that their current rheum reps to call on. I think that the RSAMs are pretty safe for awhile…as safe as one can be in this industry.
Click to expand...

Except you are forgetting they bought chemocentryx who call on Rhuem and Neph. And full of Horizon rejects who already know Krystexxa. I predict 50% or more RSAM gone....95% NSAM and 100% referral. Especially once they figure out we make a $1 on 340b scripts which gets rid of 75% or more of your targets.

But at least we will have a great Vegas meeting! Thanks master negotiator Tim who looked out for all of us. $116.50
 




anonymous said:
Except you are forgetting they bought chemocentryx who call on Rhuem and Neph. And full of Horizon rejects who already know Krystexxa. I predict 50% or more RSAM gone....95% NSAM and 100% referral. Especially once they figure out we make a $1 on 340b scripts which gets rid of 75% or more of your targets.

But at least we will have a great Vegas meeting! Thanks master negotiator Tim who looked out for all of us. $116.50
Click to expand...


Like the other poster stated, this isn’t primary care where you carry multiple drugs. Chemocentryx reps are irrelevant. They don’t even have very many reps.
I do agree that the Neph team will be dissolved, sooner rather than later

And, yes, I still can’t believe that the national meeting was his “dealbreaker”. It’s hard enough to fake being happy & engaged at these meeting under normal circumstances. This will be brutal.
 





Write your reply...
Top Bottom
Back
Quote